Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...
Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...
Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session on future therapy targets ...
Daniel Petrylak shares interim results from Duravelo-2, a study of zelenectide in patients with one prior line of therapy for metastatic urothelial carcinoma. Zelenectide is a bicyclic peptide ...
The fourth episode in this podcast series features a discussion between the two principal investigators from the phase III EMBARK trial (NCT02319837). EMBARK showed that in patients with prostate ...
Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson PIVOT-006 Trial: Cretostimogene Grenadenorepvec for Intermediate-Risk Non-Muscle Invasive Bladder ...
Juan Ruiz-Bañobre presents an ultrasensitive ctDNA analysis in advanced clear cell RCC, using a tumor-informed whole genome sequencing assay on serial plasma samples from 37 treatment-naive patients ...
(UroToday.com) The 2026 ASCO annual meeting featured a bladder cancer session and a presentation by Dr. Earle Burgess discussing clinical outcomes with ERBB2 gene amplification and activating ...
Ronald Chen presents quality of life results from the AMBASSADOR trial, a randomized study of adjuvant pembrolizumab versus observation in high-risk urothelial carcinoma after radical surgery. Quality ...
Non-Interventional and Medical Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia in Men: Guidelines of the French LUTS Committee (CTMH) - Beyond the Abstract ...
ASCO GU 2023 Press Releases Clinical Data Presented at ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC Cabometyx® in Combination with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results